alfuzosin hydrochloride / Generic mfg. - LARVOL DELTA

Differential Risks of Dementia, Depression, and Injury Among Common α-Blockers, with Tamsulosin as the Reference Drug: A Real-World Cohort Study in Men with Lower Urinary Tract Symptoms. (PubMed, J Clin Med) - "Patients were grouped by α-blocker type-tamsulosin, doxazosin, terazosin, alfuzosin, silodosin, or prazosin-and matched 1:1 using propensity scores to adjust for demographic, clinical, and psychosocial variables. Given its favorable profile, alfuzosin may be the preferred agent in patients at elevated risk of cognitive or psychiatric disorders. These findings highlight the need for individualized α-blocker selection and long-term pharmacovigilance in BPH management."

Journal • Real-world evidence • Alzheimer's Disease • Benign Prostatic Hyperplasia • CNS Disorders • Dementia • Depression • Mental Retardation • Oncology • Psychiatry

Non-Catalytic Inhibitors of the p38/MK2 Interface: Repurposing Approved Drugs to Target Neuroinflammation in Alzheimer's Disease. (PubMed, J Med Chem) - "Virtual screening of FDA-approved drugs prioritized nilotinib, a BCR-ABL inhibitor, as a putative PPI disruptor...Guided by these findings, we developed a lysate-based TR-FRET ultrahigh-throughput assay that identified additional inhibitors, including α1-adrenergic antagonists doxazosin, terazosin, and alfuzosin. These compounds suppressed cytokine induction via docking groove blockade. Together, these results establish a non-ATP-competitive approach for selectively targeting the p38/MK2 complex and highlight the translational potential of drug repurposing to modulate neuroinflammation in Alzheimer's disease."

Journal • Alzheimer's Disease • CNS Disorders • Inflammation • ABL1 • BCR

Silodosin in treating men With BPH-associated lower urinary tract Symptoms: A systematic review and network meta-analysis. (PubMed, Int J Surg) - "Silodosin is highly effective for BPH-LUTS, particularly for voiding symptoms, but carries a elevated risk of ejaculatory dysfunction. Combination with tadalafil may enhance urinary flow. Clinicians should weigh efficacy against adverse events; further trials are needed to confirm long-term benefits."

Journal • Retrospective data • Benign Prostatic Hyperplasia

Alfuzosin-Induced Autoimmune Hepatitis: A Rare Case Report. (PubMed, Turk J Gastroenterol) - No abstract available

Journal • Autoimmune Hepatitis • Immunology • Inflammation

Development and Characterization of Sensitive, Eco-Friendly, and Selective Microwave-Aided Fluorodensitometric Probe for Estimation of Alfuzosin Using Comprehensive Approach of Multicolored Analytical Chemistry and Design of Experiments. (PubMed, Luminescence) - "The method was successfully applied to pharmaceutical formulations and different plasma samples. The proposed method offers a sensitive, selective, and environmentally friendly approach for AFZ estimation at picoscale levels, adhering to white analytical chemistry principles and the QbD approach."

Journal

Management of acute urinary retention in men with benign prostatic hyperplasia: Literature review and guidelines from the French Urological Association Male LUTS Panel (CTMH). (PubMed, Fr J Urol) - "These CTMH guidelines provide evidence-based recommendations for AUR management, emphasizing alpha-blocker therapy before trial without catheter and considering patient-specific factors when selecting drainage methods. Further research is needed to optimize surgical timing and technique selection."

Clinical guideline • Journal • Review • Anesthesia • Benign Prostatic Hyperplasia

The Discovery of α-Adrenoceptor Antagonists as a Potential New Treatment Option for Uveal Melanoma. (PubMed, Biomolecules) - "Drug screening with UM spheroids revealed that prazosin and doxazosin dose-dependently reduced viability, whereas terazosin, alfuzosin, silodosin, tamsulosin, and phenoxybenzamine were found to be inefficient. This suggests a tumor-preventive effect through the blockade of α1A-AR. The present study highlights the responses of UM spheroids to α-AR antagonists and demonstrates that prazosin, doxazosin, or RS17053 may be a treatment option for preventing UM tumor recurrence or metastasis."

Journal • Eye Cancer • Hepatocellular Cancer • Melanoma • Ocular Melanoma • Oncology • Solid Tumor • Uveal Melanoma • AR

Comparison of the First Dose and Efficacy of Alfuzosin, Tamsulosin and Silodosin in the Treatment of Benign Prostatic Hyperplasia. (PubMed, Arch Esp Urol) - "Silodosin provided the most rapid symptomatic improvement following initial administration, likely due to its high α1A-receptor selectivity. However, by the third month, all three agents showed similar clinical efficacy, supporting their use as viable treatment options tailored to patient-specific needs."

Clinical • Journal • Retrospective data • Benign Prostatic Hyperplasia

Efficacy of Hexanic Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study. (PubMed, Prostate) - "The combination of HESr and alfuzosin was significantly more effective than alfuzosin monotherapy in relieving LUTS, with greater benefits from Month 3 onward. Qmax and nocturia also showed greater, although mild, improvements with combination therapy. Sexual function outcomes were comparable between groups. High adherence and real-world applicability support the clinical value of this combination in managing BPH-related LUTS."

Journal • Benign Prostatic Hyperplasia • Inflammation

Novel Compounds in Targeting the α1-adrenoceptor for Antihypertensive Therapy. (PubMed, Cardiovasc Hematol Agents Med Chem) - "Terazosin, doxazosin, tamsulosin, and alfuzosin are examples of α1-adrenoceptor antagonists that have antihypertensive properties; however, they are linked to considerable side effects, including headaches, dizziness, reproductive problems, and postural hypotension. In the last several years, a number of novel α1-adrenergic antagonists have been synthesised by modifications of various pharmacophores such as Isochroman-4-one, Quinazolines, Piperazine, and Quinazoline-triazole, etc. The present review highlights recently synthesized α1-adrenoceptor antagonists for the management of hypertension, and emphasizes their structure-activity relationship and subtype selectivity."

Journal • Cardiovascular • Hypertension • Hypotension • Myocardial Infarction • Pain

Electromotive Drug Administration in the Porcine Ureter: First In Vivo Application for Ureteral Dilation. (PubMed, J Endourol) - "Neither aminophylline nor isoproterenol with EMDA resulted in a significant increase in ureteral size compared with their respective NS controls (aminophylline vs NS, 0.3 Fr vs -0.6 Fr, p = 0.344; isoproterenol vs NS, 0.1 Fr vs -0.4 Fr, p = 0.125). In this first report, EMDA-mediated in vivo delivery of alfuzosin into the porcine ureter acutely increased ureteral distensibility."

Journal • Preclinical

Prophylactic alpha-blockers for prevention of post-operative urinary retention after total mesorectal excision for cancer: A prospective multicenter study from the GRECCAR group (ESCP 2025) - "LOS was significantly shorter with Alfuzosin compared to both standard care(6 days [2-60] vs. 10 days [4-72],p<0.001) and Silodosin(8 days [5–40],p<0.001). Conclusion Prophylactic Alfuzosin significantly reduces post-operative urinary retention and re-catheterization rate after TME with a shorter LOS.This Alfuzosin protocol should be implemented in early rehabilitation programs in order to improve postoperative outcomes after rectal surgery."

Clinical • Benign Prostatic Hyperplasia • Colorectal Cancer • Oncology • Prostate Cancer • Rectal Cancer • Solid Tumor

Prostatitis: A Review. (PubMed, JAMA) - "First-line therapy for chronic bacterial prostatitis is a minimum 4-week course of levofloxacin or ciprofloxacin...First-line oral therapy for CP/CPPS with urinary symptoms is α-blockers (eg, tamsulosin, alfuzosin; ΔNIH-CPSI score difference vs placebo = -10.8 to -4.8). Other oral therapies are associated with modest changes in NIH-CPSI score compared with placebo, including anti-inflammatory drugs (eg, ibuprofen; ΔNIH-CPSI score difference = -2.5 to -1.7), pregabalin (ΔNIH-CPSI score difference = -2.4), and pollen extract (ΔNIH-CPSI score difference = -2.49). Prostatitis includes acute bacterial prostatitis, chronic bacterial prostatitis, and CP/CPPS, each of which is diagnosed and treated differently. First-line treatments are broad-spectrum antibiotics for acute bacterial prostatitis (such as piperacillin-tazobactam, ceftriaxone, or ciprofloxacin), at least 4 weeks of fluoroquinolones for chronic bacterial prostatitis, and α-blockers for CP/CPPS with urinary symptoms."

Journal • Gynecology • Infectious Disease • Musculoskeletal Pain • Nephrology • Oncology • Pain

Alfuzosin and Mirabegron for Double-J Stent Symptoms (clinicaltrials.gov) - P=N/A | N=100 | Completed | Sponsor: University of Gaziantep

New trial

An eco-friendly HPLC method for the sustainable analysis of the newly approved combinations of Alfuzosin and Tamsulosin, with Tadalafil in organic-solvent-free mixed-micellar systems. (PubMed, Analyst) - "Greenness of the method was assessed using the Analytical GREEnness metric approach (AGREE), and the blueness was assessed using blue applicability grade index (BAGI), with scores of 0.76 and 82.5, respectively. These scores underline the superiority of the proposed procedure over previously reported methods."

Journal • Benign Prostatic Hyperplasia • Urology

Electromotive Drug Administration (EMDA) in the Porcine Ureter: First Report of In Vivo Ureteral Dilation Following Alfuzosin Infusion (AUA 2025) - "Ureteral infusion of AFZ using EMDA resulted in higher levels of drug penetration and a significant increase in porcine ureteral distensibility."

Preclinical

The Beneficial Effects of Alpha-Blockers, Antimuscarinics, Beta 3-Agonist, and PDE5-Inhibitors for Ureteral Stent-Related Discomfort: A Systematic Review and Meta-Analysis from KSER Update Series. (PubMed, Medicina (Kaunas)) - "This study utilized a network meta-analysis to evaluate stent-related discomfort (SRD) in patients with alpha-blockers (alfuzosin, tamsulosin, and silodosin), antimuscarinics (solifenacin), beta 3-agonists (mirabegron), and phosphodiesterase 5-inhibitors (tadalafil) versus a placebo. Compared with the placebo, solifenacin, tamsulosin, and alfuzosin significantly decreased the USS. In our study, solifenacin may be considered the most effective medication for SRD."

Clinical • Journal • Retrospective data • Review • Renal Calculi • Urolithiasis • Urology

α-Adrenoreceptor blocker phentolamine inhibits voltage-gated sodium channels via the local anaesthetic binding site. (PubMed, Br J Pharmacol) - "Phentolamine blocks voltage-gated sodium channels via the local anaesthetic receptor site. This may conflict with its current indication as an antidote for local anaesthetics. We propose alternative α-adrenoreceptor antagonists as possible candidates for local anaesthetic reversal because these are less potent inhibitors of both cardiac and neuronal voltage-gated sodium channels."

Journal • Anesthesia • Pain • NAV1

Drug-induced dementia: a pharmacovigilance analysis of the FAERS database. (PubMed, Expert Opin Drug Saf) - "Besides neurological drugs, the drugs with the highest number of reports are apixaban, valsartan and atorvastatin. We found that tamsulosin, alfuzosin, and megestrol may be associated with an increased risk of dementia, and further research is required to clarify these relationships. In clinical practice, it is important to monitor the cognitive status of patients when using drugs that may increase the risk of dementia."

Adverse events • Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Dementia

Alpha-adrenergic antagonists and iris dynamics: Challenges and solutions in cataract surgery. (PubMed, BMC Ophthalmol) - "α1-ARAs have implications for pupil size regulation and surgical procedures involving the eye. Tamsulosin is more potent than alfuzosin in inducing IFIS. Systemic α1-ARAs lower values of DMR thickness, DMR/SMR ratio and reduces pupillary diameter. Therefore, ophthalmologists, primary care physicians, urologists, and patients should be aware of the potential difficulties that these drugs pose for cataract surgery."

Journal • Surgery • Benign Prostatic Hyperplasia • Cardiovascular • Cataract • Hypertension • Ophthalmology • Urology • ADRA1B

Association Between Alpha-1 Adrenoreceptor Antagonist Use and Cognitive Impairment: A Systematic Review. (PubMed, Int Neurourol J) - "Tamsulosin was associated with no cognitive dysfunction in 2 RCTs, increased risk for dementia in 2 non-RCTs, no change in cognition in 1 non-RCT, and decreased risk for dementia in 1 non-RCT. Among 3 non-RCTs analyzing alfuzosin, it was associated with decreased risk of or no association with dementia in 2 studies and increased risk for dementia in 1 study. Doxazosin, prazosin, and terazosin were neutral or showed a negative risk for dementia...Considering the existing literature, it is appropriate to use α1-AR antagonists without concern for cognitive dysfunction. Future research, through robust study designs considering the multifactorial nature of cognitive dysfunction, is required to further evaluate this association."

Journal • Review • Alzheimer's Disease • Benign Prostatic Hyperplasia • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • Hypertension • ADRA1B

Clinical features and management approaches for Urinary Incontinence in Older Adults: Evidence from Three Hospitals in Qatar. (PubMed, Nepal J Epidemiol) - "Solifenacin (24.9%), Tolterodine (4.1%), and Oxybutynin (1.1%) were the most commonly administered anticholinergic drugs, while Tamsulosin (82.9%), Alfuzosin (14.5%), and Doxazosin (1.7%) were the most frequently prescribed alpha-blockers. This study also highlights the need for thorough documentation of the diagnosis and reasons for improving the standards of patient care. The findings of this study provide important information that can be used to design medication management methods for enhancing patient outcomes."

Journal • Geriatric Disorders • Urinary Incontinence • Urology

Tamsulosin use in benign prostatic hyperplasia and risks of Parkinson's disease, Alzheimer's disease and mortality: An observational cohort study of elderly Medicare enrollees. (PubMed, PLoS One) - "The study analyzed 1.1 million patients for a mean follow-up period of 3.1 years from being prescribed one of the study drugs. For all outcomes, patients on tamsulosin were used as the reference for comparison. For mortality, alfuzosin was associated with 27% risk reduction (HR 0.73, 95%CI 0.68-0.78), and doxazosin with 6% risk reduction (HR 0.94, 95%CI 0.91-0.97). For Parkinson's disease, terazosin was associated with 26% risk reduction (HR 0.74, 95%CI 0.66-0.83), and doxazosin with 21% risk reduction (HR 0.79, 95%CI 0.72-0.88). For Alzheimer's disease, terazosin was associated with 27% risk reduction (HR 0.73, 95%CI 0.65-0.82), and doxazosin with 16% risk reduction (HR 0.84, 95%CI 0.76-0.92). Tadalafil was associated with risk reduction (27-40%) in all 3 outcomes. More research is needed to elucidate the underlying mechanisms of these observations. Given the availability of safer alternatives for treating benign prostatic hyperplasia, caution should be..."

Journal • Medicare • Observational data • Reimbursement • US reimbursement • Alzheimer's Disease • Benign Prostatic Hyperplasia • CNS Disorders • Movement Disorders • Parkinson's Disease

Synthesis of diversely substituted quinazoline-2,4(1H,3H)-diones by cyclization of tert-butyl (2-cyanoaryl)carbamates. (PubMed, Org Biomol Chem) - "This strategy can be utilized for the simplified synthesis of goshuyuamide II and an alkaloid isolated from Zanthoxylum arborescens in good yields. This method was also applied to the synthesis of quinazoline-2,4(1H,3H)-diones that are precursors of medicinally important compounds: alfuzosin, terazosin, prazosin, IAAP, doxazosin, FK 366 (zenarestat) and KF31327."

Journal

Association of Terazosin, Doxazosin, or Alfuzosin Use and Risk of Dementia With Lewy Bodies in Men. (PubMed, Neurology) - "We find an association in men who are taking Tz/Dz/Az and a lower hazard of DLB compared with similar men taking other medications. When combined with the literature of Tz/Dz/Az on Parkinson disease, our findings suggest that glycolysis-enhancing drugs may be broadly protective in neurodegenerative synucleinopathies. A future randomized trial is required to assess these associations for causality."

Journal • Alzheimer's Disease • Benign Prostatic Hyperplasia • CNS Disorders • Cognitive Disorders • Dementia • Lewy Body Disease • Movement Disorders • Parkinson's Disease